Michael Smolinski - 03 Aug 2021 Form 3 Insider Report for Athenex, Inc.

Role
Chief Scientific Officer
Signature
/s/ Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Aug 2021
Net transactions value
$0
Form type
3
Filing time
27 Oct 2021, 16:16:02 UTC
Next filing
10 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 5,173 03 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 1,600 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 4,000 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 4,200 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 4,000 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 6,928 $5.50 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 10,000 $5.50 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 10,000 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 7,500 $17.30 Direct F1
holding ATNXQ Stock Option (Right to Buy) 03 Aug 2021 Common Stock 24,000 $10.26 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on March 27, 2019.
F2 This option vests in four equal annual installments beginning on August 27, 2021.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney